Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors

Publication date: Available online 18 January 2019Source: Revista Clínica Española (English Edition)Author(s): D. León Jiménez, R. Gómez Huelgas, A.J. Fernández Romero, J.M. López Chozas, L. Pérez de Isla, J.P. Miramontes GonzálezAbstractSodium-glucose cotransporter-2 inhibitors have changed the concept of the effects that hypoglycemic drugs have on hearth failure (HF). For the first time, a therapeutic group has modified the evolution of HF. Its effect goes beyond glycemic control, and different theories have been postulated to justify this benefit. In the article we sent, we analyze the influence of the different pharmacological groups used in type 2 diabetes mellitus on HF, and we present the theory of the mechanism of action associated with the benefit of these drugs. In our opinion, this benefit in HF is secondary to its diuretic effect, specifically an effect very similar to carbon dioxide inhibitors.We think that our theory is novel, explains the mechanism of action and we have not found in the literature any article that explains the mechanism of action in such a precise way.ResumenLos inhibidores del cotransportador sodio-glucosa tipo 2 han cambiado el concepto que se tenía de los efectos que ejercen los fármacos hipoglucemiantes sobre la insuficiencia cardiaca (IC). Es la primera vez que un grupo terapéutico modifica la evolución de la IC. Sus efectos trascienden al control glucémico, postulándose diferentes teorías para justificar estos beneficios. ...
Source: Revista Clinica Espanola - Category: Internal Medicine Source Type: research